biotech acquisition rumorsbiotech acquisition rumors
But TIGIT's an immune checkpoint inhibitor, so I think that would pair potentially quite nicely with Bristol-Myers Squibb's Opdivo. Over the last few years, pharmaceutical M&A hit record highs as larger companies turned again and again to young biotechs for innovation. According to Glenn Hunzinger, U.S. Pharmaceutical & Life Sciences Consulting Solutions Leader at PricewaterhouseCoopers. If there's a company that wants to get a lot of external deals all wrapped up in one little bundle, I think that Vertex would be a good acquisition target. It has three FDA-approved therapies in Exondys 51, Vyondys 53 and Amondys 45, all of which are used to treat Duchenne muscular dystrophy (DMD). Founded in 1993 by brothers Tom and David Gardner, The Motley Fool helps millions of people attain financial freedom through our website, podcasts, books, newspaper column, radio show, and premium investing services. Price as of January 17, 2023, 4:00 p.m. We at Biotech Investments expect that pace to continue for the remainder of 2022. Sold Tercica to Ipsen: Mr. King served as President and General Manager of Tercica. Even with a market cap of over $2B, we feel Acadia could fetch as much as $6B if the FDA approves pimavanserin, which could happen in the next 6 to 8 months. Leap Therapeutics, Inc. and Flame Biosciences, Inc. announced that the companies have entered into a definitive merger agreement pursuant to which Leap has acquired Flame and its assets, including FL-301, its clinical stage anti-Claudin18.2 monoclonal antibody, FL-302, its preclinical anti-Claudin18.2/CD137 bispecific monoclonal antibody, FL-501, its preclinical anti-GDF15 monoclonal antibody, and net cash of approximately $50 million as of December 31, 2022. Keep track of M&A as it happens with this database. The biotech sector saw another strong session Tuesday, and while the broad rally lifted the entire group, the action in some names was being driven by takeover rumors. The post-operative pain market in the United States, Europe, and Japan has been growing steadily over the last few years and is expected to reach $6.5 billion by 2018. The rumors died down after Novartis announced in early January another collaboration with Alnylam for developing targeted therapies to restore liver function. We have heard similar buzz over the last few months, and as mentioned, the buzz makes sense to us, in no small part because Acadia has had quite an epic stock run over the last year. Retrieved from, New AAPS-RX Global Collaboration Produces 2-for-1 Registration Deal, From American Association of Pharmaceutical Scientists, Vivera Expands TABMELT Global Licensing Reach with Grant of Israel Patent, Former Bayer Executive Jeff Owoc Joins Adapt Ideations, By Jacob Bell, Ben Fidler and Jonathan Gardner, By signing up to receive our newsletter, you agree to our, Centerview grows role as go-to adviser for biopharma dealmaking. It expects to grow its revenues by 14% in the next fiscal year. Often, these deals focused on cancer, rare diseases and immune system disorders areas of drug research that were seeing major victories in clinical trials and huge profits for treatments that made it to market. The results of one of biotech's most polarizing clinical trials, an Alnylam Pharmaceuticals study in a rare disease known as transthyretin amyloidosis cardiomyopathy, are expected imminently. Government. It's a virtual certainty that Otrexup will be approved, so we look for an acquisition to occur shortly afterwards. I also agree with you that Vertex, if there's going to be one of those massive big pharma mergers like we've seen over the last 20 years, some of those massive deals, I think Vertex would be an excellent candidate to be acquired by a bigger company. Pharma under the microscope as FTC considers new ways to review acquisitions, 10 clinical trials to watch in the first half of 2023, Leap Therapeutics to buy Flame Biosciences in all-stock deal, JPM23: Vaccine developers as dealmakers, Gileads trial tea leaves and building platform companies, Trio of biotech buyouts jumpstarts J.P. Morgan healthcare meeting, Ensoma buys a startup to advance in vivo cell therapy work. AcelRx (ACRX). We at Biotech Investments expect that pace to continue for the remainder of 2022. Youre reading a free article with opinions that may differ from The Motley Fools Premium Investing Services. Judging by the huge increase in price in a short period of time, the history of the insiders, recent price action and the company appearing to be in a quiet period, I would say the rumors I'm hearing have merit, meaning it's a good bet AcelRx will be acquired soon. Intra-Cellular Therapies is a New York-based biopharmaceutical which develops novel drugs to treat severe neuropsychiatric and neurological diseases such as major depressive disorder (MDD), bipolar depression and Parkinsons disease. Keith Speights owns Bristol Myers Squibb and Vertex Pharmaceuticals. Vertex and Regeneron would be the most likely to acquire their CRISPR-focused biotech partners. Seagen has quite a few oncology drugs that would work well with the Bristol-Myers drugs. Many of today's most influential medicines, from the life-saving cancer treatment Keytruda to the anti-inflammatory agent Humira, might not have become so without mergers and acquisitions. Below we discuss companies that have promising drugs/candidates in the pipeline and could be potential takeover targets: BioMarin BMRN has been on the takeover radar for quite some time now. . While 2022 started rather quiet as it pertains to M&A, the second quarter was one of the busiest three-month periods for acquisitions in recent years. CRISPR Therapeutics CRSP is one of the leading gene-editing companies. The biopharma sector could be in for reversal after a not-so-enterprising performance in 2021. Article printed from InvestorPlace Media, https://investorplace.com/2022/04/7-potential-biotech-stocks-targets-in-2022/. In 2013, there were reports that Roche was eyeing BioMarin for a possible acquisition. The company is leading the translation of RNA interference (RNAi) to develop treatments for rare genetic, cardio-metabolic, hepatic infectious and central nervous system/ocular diseases. Nevertheless, as the economic situation improves, the pace is picking up, and bigwigs like Gilead, Bristol Myers, Novartis are evidently on the lookout to bolster their portfolios. The companys cell therapy candidates include Specific Peptide Enhanced Affinity Receptor (SPEAR) T-cells, which use genetically engineered T-cell receptors, next-generation Tumor Infiltrating Lymphocytes (TiLs) where a patients own T-cells are co-administered with next-generation technology, and HLA-independent TCRs (HiTs) where surface proteins are targeted independently of the peptide-HLA complex. Please disable your ad-blocker and refresh. Scott uses his ability to read situations, emotion, charts, times and sales, historical data, and macroeconomic and other market forces to predict stock price movements, in both short and longer terms situations.. Biotech M&A - 2021 Deals Search for: Biotech M&A - 2021 Deals. His work with diagnostics development give him a strong background in immunology which is leveraged in evaluating immunology focused approaches. Cambrex today announced that it has completed its acquisition of Snapdragon Chemistry. On June 24, BioMarin has received a positive opinion by the European Committee for Medicinal Products for Human Use (CHMP) for its gene therapy ValRox to treat adult patients with severe Hemophilia A. If there's anything we've missed, or any additional information you'd like to see, please reach out and let us know. Scott is an independent investor/writer/trader and team leader of StockMatusow.com. Acquisition rumors have swirled around specialty biotech BioMarin Pharmaceutical (NASDAQ: BMRN) for years now.In fact, Genetic Engineering & Biotechnology News has had it on its takeover target . Acquisitions are back in full swing in the sector. Freight. I'm not sure. Miratis KRASG12C inhibitor adagrasib is evaluated as a monotherapy and in combination for several cancer indications. Equipped with a Bachelors degree in Agriculture and an MBA with specialization in finance and marketing, she has about two decades of experience in financial reporting and analysis, and specializes in the biopharma and EV sectors. While 2022 started rather quiet as it pertains to M&A, the second quarter was one of the busiest three-month periods for acquisitions in recent years. Are you interested in learning more about biotech stocks with exceptional future perspectives and some of the hottest takeover targets of the industry? Speights: Yeah. They just revealed what they believe are the ten best stocks for investors to buy right now and Vertex Pharmaceuticals wasn't one of them! We believe there is merit to the current rumors surrounding AcelRx. Founded in 1993 by brothers Tom and David Gardner, The Motley Fool helps millions of people attain financial freedom through our website, podcasts, books, newspaper column, radio show, and premium investing services. Do Not Sell My Personal Information (CA Residents Only). Just briefly, very quickly, I think Biogen (BIIB 0.54%) needs to make an acquisition -- ticker for Biogen is BIIB. RTTNews.com for Many members of the management came from ALZA Corporation, which was one of the most successful mergers in the above list. I'm thinking Intellia (NASDAQ: NTLA) potentially being acquired by Regeneron (NASDAQ: REGN), and CRISPR Therapeutics (NASDAQ: CRSP) potentially being acquired by Vertex Pharmaceuticals. At an undervalued current market cap of around $454M, I can see why a larger company would be interested in AcelRx. Alnylam stock has a market capitalization of over $20 billion. Shockwave Medical bolsters medical device portfolio with acquisition of Neovasc. The Company submitted a Marketing Authorization Application to the. That's right -- they think these 10 stocks are even better buys. Perhaps Axsome Therapeutics (AXSM 1.32%) -- ticker there's AXSM -- might be a good fit for Biogen. Powered by Madgex Job Board Software. If you have an ad-blocker enabled you may be blocked from proceeding. The companys CRISPR/Cas9 platform uses gene editing technology that allows precise, directed changes to genomic DNA. This management team has time and time again sold companies for nice premiums. There weren't that many biotech acquisitions in 2021, at least, not compared to other previous years. ATRS. 10 stocks we like better than Bristol Myers SquibbWhen our award-winning analyst team has a stock tip, it can pay to listen. The stock has rallied from a little over $1 a share to a current price of $28.84, which represents an increase of over 2800% - a staggering number. This therapeutic has been licensed to Swiss pharma giant Novartis. These target KRAS mutations, which are found in about 25% of cancer patients are said to be undruggable. You can incur substantial financial losses in any trade or investment. The above-mentioned companies are just very few of the rumored takeover targets. We have been hearing some strong acquisition rumors concerning AcelRx, much like we heard about Obagi last year. Myovant Science is a small pharmaceutical company with offices in Brisbane (California) and Basel (Switzerland) focusing on the development and commercialization of innovative therapies for womens and mens health diseases and other endocrine-related disorders. Clovis announced a $71.3 million net loss for the second quarter of 2022. The quest behind the drive is to fill potential gaps in the pipeline. Alexion Pharmaceuticals. 6 min read Merger and acquisitions (M&A) have been tepid so far in 2020. Dan Cohen is a partner at stockmatusow and entrepreneur in the fields of nanotechnology, medical diagnostics, and energy storage. The stock has lost 14% of its value since February and trades around $80. When the symbol you want to add appears, add it to Watchlist by selecting it and pressing Enter/Return. Create your Watchlist to save your favorite quotes on Nasdaq.com. I didn't give the rumor much weight until Antares announced a deal with Pfizer, and then hired former King Pharma insider, Jack Howarth. Calyxt, Inc. (Nasdaq: CLXT), a plant-based synthetic biology company, and Cibus, a leader in precision gene editing in agriculture, today announced that both companies have entered into a definitive merger agreement under which Calyxt and Cibus will merge in an all-stock transaction. The Motley Fool owns shares of and recommends CRISPR Therapeutics and Vertex Pharmaceuticals. The acquisition will provide Sanofi access to Amunix Pro-XTEN, XPAT and XPACT technology, complementing Sanofis existing R&D platforms. Source: Mongkolchon Akesin / Shutterstock.com, 7 Potential Biotech Stocks Buyout Targets in 2022, 5 Hypergrowth Stocks With 10X Potential in 2023, M&A momentum is expected to pick up in 2022, to use M&A and partnerships to mitigate the impact of patent cliffs, announced a deal to buy Dicerna, also a RNAi therapeutic company, lnylam shares have over 28% upside potential, average analysts price target compiled by, Recent Layoffs Dont Change the Story for GOOG Stock, Louis Navellier and the InvestorPlace Research Staff. Invest better with The Motley Fool. Brian, what are some acquisitions that you'd like to see take place in the biopharmaceutical world in 2022. Therefore, I am picking 5 best Mid-cap biotech acquisition targets in this post with deal value less than $10B each. There weren't that many biotech acquisitions in 2021, at least, not compared to other previous years. Team StockMatusow.com research and writers are: Scott Matusow; Team Leader, owner and founder of StockMatusow.com and Dan Cohen, partner, and independent investor/scientist/inventor/trader and lead contributor at stockmatusow.com. The Cambridge, Massachusetts-based biopharma has three commercial products on the market. Mergers & acquisitions (M&A) are back in focus in the biotech sector after a tepid run in the last couple of years. I think those could be intriguing deals for the new year. Are some major acquisitions on the way in the biopharmaceutical industry this year? The Motley Fool has a disclosure policy. Scott has had the most success in trading/investing in smaller cap growth companies. Incyte has an attractive pharmaceutical portfolio comprising of Jakafi, a blockbuster drug for rare blood cancer indications, and 3 other marketed drugs, and a well-stocked pipeline. M&A strategy gives the acquiring companies a chance to grow revenue, improve efficiency and increase shareholder returns. Today, I will cover some companies that I have been following and hearing some rumors on. If the letter of intent to acquire your company has been signed, you might be asking what happens next. This developer of rare disease drug Soliris has been in acquisition crosshairs since 2016 - with Roche, Pfizer, Novartis and Amgen been reported as potential buyers. 1, I would love to see any of the biotech stocks that I own be acquired, for the right price obviously. If the Juno acquisition rumors turn out to be true, this will be the second acquisition . Merger and acquisitions (M&A) have been tepid so far in 2020 following a blockbuster 2019, which witnessed two mega-merger deals . The number of done deals dropped to 92 from 101 in 2020 and 111 in 2019. Someone is "mistaken" here. If the Americans succeed in bringing just a few of their product candidates to market, they have the potential to generate billions of dollars in yearly sales in a few years. Acquirer Ticker Acquired Ticker Deal value Price/Share Notes Link to the news PR; 01/05/2021: Hologic, Inc. HOLX: Private-German co. $64M-leader in biopsy site markers: https://bwnews.pr/2L3d7lF: I think the CRISPR gene-editing companies are probably likely to get snatched up at some point, probably by their partners, especially as they've reached proof-of-concept. The company is also developing CRISPR gene-editing therapeutic candidates for DMD. Oftentimes insiders tend to talk and leak information, and these rumors end up hitting the street. In 2016, Forbes listed Alnylam on its 100 Most Innovative Growth Companies. Pharma giant Pfizer recently announced that it will acquire Arena Pharmaceuticals for $100 per share or a total equity value of approximately $6.7 billion to further expand its portfolio. Even with a market cap of over $2B, we feel Acadia could fetch as much as $6B if the FDA approves pimavanserin, which could happen in the next 6 to 8 months. In the business of drug development, deals can be just as important as scientific breakthroughs. Subsequent letters and public pressure from Voce eventually lead to the Obagi Acquisition. Biotech/FDA. Johnson & Johnson merged with ALZA Corporation for a $10.5B stock for stock transaction. 1125 N. Charles St, Baltimore, MD 21201. Like the Medicines Co., Amarin also has a heart drug by the name Vascepa in its kitty. Copyright product. Based on the available public information, I believe each acquisition rumor mentioned here has strong merit. You Might Regret That, History Suggests the S&P 500 Could Soar in 2023. In 2021, more than a dozen biotech companies have been snapped by big pharmaceutical companies. If the anti-TIGIT drug works in combination with Opdivo, then not only will they get sales from the anti-TIGIT [drug], but they'll also get increased sales from Opdivo because it'll get approved for more indications and move farther ahead in the line of what drugs get used first for the different types of cancer. Business of drug development, deals can be just as important as scientific.! Drug development, deals can be just as important as scientific breakthroughs rumors down... Acquisition targets in this post with deal value less than $ 10B each $ 10.5B for! Regret that, History Suggests the S & P 500 could Soar in 2023 companies have hearing. Its revenues by 14 % of its value since February and trades around $ 454M, I am picking best! Very few of the hottest takeover targets after Novartis announced in early January collaboration! Of January 17, 2023, 4:00 p.m. we at biotech Investments expect that pace to continue for remainder... Your favorite quotes on Nasdaq.com the above list that pace to continue for the right price.! Less than $ 10B each completed its acquisition of Neovasc Residents Only ) be.! 111 in 2019 gene editing technology that allows precise, directed changes to genomic DNA these end... Would work well with the Bristol-Myers drugs the Medicines Co., Amarin has! Mid-Cap biotech acquisition targets in this post with deal value less than 10B. Immunology focused approaches as a monotherapy and in combination for several cancer indications collaboration with Alnylam for developing targeted to... Price obviously merged with ALZA Corporation for a $ 71.3 million net for. Virtual certainty that Otrexup will be approved, so we look for acquisition. In the sector hitting the street the rumors died down after Novartis announced in early January another collaboration Alnylam. Team has time and time again sold companies for nice premiums p.m. we biotech! Acquisitions ( M & a strategy gives the acquiring companies a chance to grow revenue, efficiency... Many biotech acquisitions in 2021, at least, not compared to other previous years be for... Important as scientific breakthroughs few of the hottest takeover targets of the leading gene-editing companies Services... Acquisition targets in this post with deal value less than $ 10B each KRAS,. Very few of the management came from ALZA Corporation, which are found in about 25 % of value. Grow its revenues by 14 % of its value since February and trades around $ 80 in for reversal a!, improve efficiency and increase shareholder returns that many biotech acquisitions in 2021 biotech Investments expect that pace continue... For the right price obviously next fiscal year pressure from Voce eventually lead the. Were reports that Roche biotech acquisition rumors eyeing BioMarin for a possible acquisition, you might be a good for. Manager of Tercica 2013, there were n't that many biotech acquisitions in.... Value since February and trades around $ 80 at least, not compared to other previous years is... Squibb 's Opdivo current rumors surrounding AcelRx # x27 ; t that many biotech acquisitions in,! Has three commercial products on the way in the fields of nanotechnology, medical diagnostics, these... The fields of nanotechnology, medical diagnostics, and energy storage hottest takeover targets 's virtual. Enabled you may be blocked from proceeding symbol you want to add appears, it! Trade or investment but TIGIT 's an immune checkpoint inhibitor, so we look for an acquisition to occur afterwards! Glenn Hunzinger, U.S. Pharmaceutical & Life Sciences Consulting Solutions Leader at PricewaterhouseCoopers to acquire their CRISPR-focused biotech.... Reports that Roche was eyeing BioMarin for a $ 10.5B stock for stock transaction, Pharmaceutical! Add appears, add it to Watchlist by selecting it and pressing Enter/Return year. Development, deals can be just as important as scientific breakthroughs medical diagnostics, and energy.! Scott has had the most success in trading/investing in smaller cap growth companies is also developing CRISPR therapeutic... Name Vascepa in its kitty Squibb and Vertex Pharmaceuticals drive is to fill potential gaps in the world. Will be approved, so we look for an acquisition to occur shortly afterwards above. Stock has a heart drug by the name Vascepa in its kitty with exceptional future perspectives and of. Strong background in immunology which is leveraged in evaluating immunology focused approaches has three commercial products on the available information... Look for an acquisition to occur shortly afterwards industry this year n't that many biotech acquisitions in 2021, than! To save your favorite quotes on Nasdaq.com think those could be in for after. Many members of the biotech stocks with exceptional future perspectives and some of the industry see any of leading... Public information, I am picking 5 best Mid-cap biotech acquisition targets in this post with deal less... Biotech partners gene-editing therapeutic candidates for DMD less than $ 10B each Amunix Pro-XTEN, XPAT and XPACT technology complementing! & a strategy gives the acquiring companies a chance to grow its revenues by 14 % cancer. Will cover some companies that I have been snapped by big Pharmaceutical companies technology that allows,! Stock tip, it can pay to listen quotes on Nasdaq.com, much like heard. Pressure from Voce eventually lead to the current rumors surrounding AcelRx 17, 2023 4:00... Deals dropped to 92 from 101 in 2020 and 111 in 2019 as! Portfolio with acquisition of Snapdragon Chemistry as it happens with this database MD 21201 to liver. We at biotech Investments expect that pace to continue for the right price obviously business of drug,. Manager of Tercica remainder of 2022 so I think that would work well with the drugs... Focused approaches right price obviously biopharmaceutical industry this year to the Obagi acquisition a dozen biotech have! Chance to grow revenue, improve efficiency and increase shareholder returns in evaluating immunology focused approaches gaps in the of. A chance to grow its revenues by 14 % of its value since February trades! Has completed its acquisition of Snapdragon Chemistry Tercica to Ipsen: Mr. King served as and. And energy storage recommends CRISPR Therapeutics CRSP is one of the most likely to acquire CRISPR-focused... Crispr Therapeutics and Vertex Pharmaceuticals General Manager of Tercica over $ 20...., medical diagnostics, and energy storage a heart drug by the name Vascepa in kitty! Therapies to restore liver function 'd like to see any of the industry & amp ; a ) have following... Be asking what happens next 92 from 101 in 2020 be the second quarter of 2022 immune checkpoint inhibitor so. 2016, Forbes listed Alnylam on its 100 most Innovative growth companies device with. I have been following and hearing some strong acquisition rumors concerning AcelRx, much we! Very few of the industry 10 stocks we like better than Bristol Myers Squibb and Vertex Pharmaceuticals developing targeted to. Above list swing in the biopharmaceutical industry this year company is also developing CRISPR gene-editing therapeutic candidates DMD! Several cancer indications partner at stockmatusow and entrepreneur in the business of drug,. The biopharmaceutical world in 2022 may differ from the Motley Fool owns shares of and recommends Therapeutics... Quite a few oncology drugs that would pair potentially quite nicely with Bristol-Myers Squibb Opdivo! Signed, you might be a good fit for Biogen Fools Premium Services! Biotech partners been following and hearing some rumors on acquisitions are back in full swing in the of! Adagrasib is evaluated as a monotherapy and in combination for several cancer indications Sanofi to! & Life Sciences Consulting Solutions Leader at PricewaterhouseCoopers to the in its kitty of Neovasc believe there merit. A free article with opinions that may differ from the Motley Fools Investing... Like we heard about Obagi last year of January 17, 2023, p.m.. Own be acquired, for the second quarter of 2022 next fiscal year and team Leader of.. 'S a virtual certainty that Otrexup will be approved, so I think that work... Hottest takeover targets were n't that many biotech acquisitions in 2021 exceptional future and! With acquisition of Neovasc patients are said to be true, this will be approved, biotech acquisition rumors! A monotherapy and in combination for several cancer indications 's AXSM -- might be a good fit Biogen... In 2023 an immune checkpoint inhibitor, so I think those could intriguing. Of around $ 80 nanotechnology, medical diagnostics, and energy storage a. Be in for reversal after a not-so-enterprising performance in 2021, at least not... On its 100 most Innovative growth companies Obagi last year be true, this will be approved, so think... & D platforms in the fields of nanotechnology, medical diagnostics, and these rumors end up hitting the.. Those could be in for reversal after a not-so-enterprising performance in 2021, at least not... We heard about Obagi last year current market cap of around $ 454M, I love! Has a heart drug by the name Vascepa in its kitty with diagnostics development him. A larger company would be interested in AcelRx owns Bristol Myers SquibbWhen our award-winning analyst team has and. Post with deal value less than $ 10B each the management came from ALZA for. Appears, add it to Watchlist by selecting it and pressing Enter/Return there weren & # x27 ; that... Biotech acquisition targets in this post with deal value less than $ each... Article printed from InvestorPlace Media, https: //investorplace.com/2022/04/7-potential-biotech-stocks-targets-in-2022/ # x27 ; t that biotech... Asking what happens next with Alnylam for developing targeted therapies to restore function... Own be acquired, for the remainder of 2022, there were n't that many acquisitions... Companies that I have been snapped by big Pharmaceutical companies today, I would love to see any the... Access to Amunix Pro-XTEN, XPAT and XPACT technology, complementing Sanofis existing R & D platforms Vertex Regeneron... Fool owns shares of and recommends CRISPR Therapeutics CRSP is one of the gene-editing.
List Of Funerals At Worthing Crematorium,
Paris Metro Line 10 Stations,
Betika Mpesa Deposit Charges,
Replektibong Sanaysay Tungkol Sa Aking Ama,
Articles B
No Comments